@article{HempelPiehlerPfaffletal.2020, author = {Hempel, Louisa and Piehler, Armin and Pfaffl, Michael W. and Molnar, Jakob and Kirchner, Benedikt and Robert, Sebastian and Veloso, Julia and Gandorfer, Beate and Trepotec, Zeljka and Mederle, Stefanie and Keim, Sabine and Milani, Valeria and Ebner, Florian and Schweneker, Katrin and Fleischmann, Bastian and Kleespies, Axel and Scheiber, Josef and Hempel, Dirk and Zehn, Dietmar}, title = {SARS-CoV-2 infections in cancer outpatients—Most infected patients are asymptomatic carriers without impact on chemotherapy}, series = {Cancer Medicine}, volume = {9}, journal = {Cancer Medicine}, number = {21}, pages = {8020 -- 8028}, year = {2020}, abstract = {Oncologic patients are regarded as the population most at risk of developing a severe course of COVID-19 due to the fact that malignant diseases and chemotherapy often weaken the immune system. In the face of the ongoing SARS-CoV-2 pandemic, how particular patients deal with this infection remains an important question. In the period between the 15 and 26 April 2020, a total of 1227 patients were tested in one of seven oncologic outpatient clinics for SARS-CoV-2, regardless of symptoms, employing RT-qPCR. Of 1227 patients, 78 (6.4\%) were tested positive of SARS-CoV-2. Only one of the patients who tested positive developed a severe form of COVID-19 with pneumonia (CURB-65 score of 2), and two patients showed mild symptoms. Fourteen of 75 asymptomatic but positively tested patients received chemotherapy or chemo-immunotherapy according to their regular therapy algorithm (±4 weeks of SARS-CoV-2 test), and 48 of 78 (61.5\%) positive-tested patients received glucocorticoids as co-medication. None of the asymptomatic infected patients showed unexpected complications due to the SARS-CoV-2 infection during the cancer treatment. These data clearly contrast the view that patients with an oncologic disease are particularly vulnerable to SARS-CoV-2 and suggest that compromising therapies could be continued or started despite the ongoing pandemic. Moreover the relatively low appearance of symptoms due to COVID-19 among patients on chemotherapy and other immunosuppressive co-medication like glucocorticoids indicate that suppressing the response capacity of the immune system reduces disease severity.}, language = {en} } @article{HempelPiehlerGandorferetal.2022, author = {Hempel, Louisa and Piehler, Armin and Gandorfer, Beate and De Oliveira, Julia Veloso and Philipp, Patrick and Robert, Sebastian and Axel, Kleespies and Schick, Cordula and Fleischmann, Bastian and Schweneker, Katrin and Milani, Valeria and Schenk, Kristina and Ebner, Florian and Donhauser, Lara and Zehn, Dietmar and Hempel, Dirk}, title = {Clinical impact of SARS-CoV-2 delta variant infection in tumor patients and the impact of vaccination on different cancer treatment regimens.}, series = {Journal of Clinical Oncology}, volume = {40}, journal = {Journal of Clinical Oncology}, number = {16_suppl}, doi = {10.1200/JCO.2022.40.16_suppl.e18750}, pages = {E18750 -- E18750}, year = {2022}, abstract = {Background: Data on SARS-CoV-2 infections in oncological patients in the outpatient settings are scarce. Methods: During the spread of the delta variant between April 2021 and September 2021, a total of 10.677 patients were tested for SARS-CoV-2 infection by RT-qPCR in seven outpatient clinics in Bavaria, Germany. Results: Within the tested patient cohort, 4.960 patients (46.5\%) suffered from a malignant disease (74\% solid tumors and 26\% malignant hematological diseases). This group was compared with 5.717 patients (53.5\%) without a malignant disease (33.1\% with other hematological diseases and 66.9\% patients without a hematological or oncological disease). During the observation period, 119 (2.4\%) patients with malignancies were tested positive (88 patients with solid tumors; 31 patients with malignant hematological diseases) compared to 115 positive patients (2.0\%) in the control group. 32 of 119 positively tested patients (26.9\%) suffering from malignant disease required hospitalization and 9/32 patients (28.1\%) died during the clinical course. Conclusions: These observations are in clear contrast to data from patients we evaluated during the pre-delta variants period between 15 and 26 April 2020 in the same seven outpatient clinics. In this period, a total of 1.227 patients were tested for SARS-CoV-2 by RT-qPCR. 78/1227 patients (6.3\%) were tested positive in RT-qPCR and most showed mild symptoms of infection. None of the SARS-CoV-2 infected patients died. These data were analyzed when no vaccination was available. These data were evaluated during a period where no vaccine was available. Vaccination of patients with malignancies with BiontechPfizer's mRNA vaccines was started in April 2021. The response to the vaccine was tested by an antibody assay (Elecsys Anti-SARS-CoV-2 S-immunoassay, Roche) at the earliest four weeks after the second vaccination. To assess the response, we compared five patient cohorts: Patients who received (i) B cell depleting antibodies, (ii) checkpoint inhibitors (ICI), (iii) chemotherapy, or (iv) tyrosin kinase inhibitors (TKIs), and (v) healthy controls. The patients treated with ICI or TKI showed a comparable vaccination response to the healthy patients, while patients receiving Rituximab/Obinutuzumab showed no significant humoral vaccination response at all. The more severe disease course of patients infected by the SARS-CoV-2 delta variant compared to the initial waves of infections strongly underline the importance of vaccination in cancer patients.}, language = {en} }